State Street Corp Has $19.64 Million Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

State Street Corp lessened its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 8.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,013,083 shares of the company's stock after selling 655,041 shares during the period. State Street Corp owned about 3.34% of Allogene Therapeutics worth $19,637,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ALLO. The Manufacturers Life Insurance Company lifted its position in shares of Allogene Therapeutics by 1.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company's stock worth $1,361,000 after acquiring an additional 5,642 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Allogene Therapeutics by 429.6% during the 2nd quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company's stock worth $25,000 after acquiring an additional 8,734 shares during the period. Arizona State Retirement System boosted its position in shares of Allogene Therapeutics by 36.1% during the 2nd quarter. Arizona State Retirement System now owns 40,915 shares of the company's stock valued at $95,000 after acquiring an additional 10,855 shares in the last quarter. Private Advisor Group LLC bought a new stake in Allogene Therapeutics in the third quarter valued at about $34,000. Finally, Federated Hermes Inc. acquired a new position in Allogene Therapeutics in the second quarter worth about $29,000. 83.63% of the stock is owned by institutional investors and hedge funds.

Allogene Therapeutics Trading Up 7.2 %

Shares of ALLO traded up $0.14 during trading hours on Tuesday, hitting $2.09. 1,810,945 shares of the stock traded hands, compared to its average volume of 2,487,045. Allogene Therapeutics, Inc. has a 1-year low of $1.78 and a 1-year high of $5.78. The firm has a market capitalization of $438.21 million, a PE ratio of -1.34 and a beta of 0.83. The business has a fifty day moving average of $2.47 and a 200-day moving average of $2.56.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research note on Friday, November 8th. Piper Sandler dropped their price objective on Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Finally, William Blair reissued an "outperform" rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $9.73.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).